Sunridge International today announced approval by China’s State Food & Drug Administration for the use in China of the company’s Pneuatic Trabeculoplasty treatment (PNT). Sunridge describes PNT as a safe, effective, 2-minute, non-invasive and cost effective alternative treatment for glaucoma and ocular hypertension. PNT has been developed, patented, and distributed by the company’s wholly owned subsidiary, Ophthalmic International.
Sunridge CEO, G. Richard Smith, provided details, emphasizing the significance of the approval to the future of Sunridge. “Our exclusive distributors, Beijing Vision World Trading Co, have informed us that they have received all necessary government documentation approving PNT as a medical treatment for glaucoma and ocular hypertension, as well as marketing approval for our equipment and disposable line of products. Along with the good news of the approval, came an initial order for 30 units and 10,000 rings. This order will allow Beijing Vision to place units in hospitals throughout China, and with sub distributors in a number of provinces. It marks the beginning of what we know will be a long and mutually profitable move into one of the world’s biggest markets where even a 10 % market share can produce millions of dollars in annual revenue to our company.”
President of Beijing Vision, Waisheng Yang, spoke of the work involved in the accomplishment. “The SFDA approval has been hard won. It marks the culmination of 3 1/2 years of consistent market development that has included multiple clinical trials in both private and state run military hospitals. It has come through the effort of a number of dedicated people and it was worth every moment. We are now ready to start our marketing operations throughout China and to reach out to its 10 million or more glaucoma patients.”